BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24963486)

  • 1. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
    Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: a systematic review and a meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Lococo F; Cafarotti S; Prior JO; Bertagna F; Ceriani L; Giovanella L
    Lung Cancer; 2014 Jan; 83(1):1-7. PubMed ID: 24290256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Lococo F; Cafarotti S; Bertagna F; Prior JO; Ceriani L; Giovanella L
    Acad Radiol; 2014 Jan; 21(1):11-20. PubMed ID: 24331260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
    Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
    Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis.
    Treglia G; Kakhki VR; Giovanella L; Sadeghi R
    Am J Clin Dermatol; 2013 Dec; 14(6):437-47. PubMed ID: 23959776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
    De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: A meta-analysis.
    Annunziata S; Pizzuto DA; Caldarella C; Galiandro F; Sadeghi R; Treglia G
    World J Gastroenterol; 2015 Oct; 21(40):11481-8. PubMed ID: 26523112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
    Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
    Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography in patients with chronic inflammatory bowel disease: a systematic review and a meta-analysis.
    Treglia G; Quartuccio N; Sadeghi R; Farchione A; Caldarella C; Bertagna F; Fania P; Cistaro A
    J Crohns Colitis; 2013 Jun; 7(5):345-54. PubMed ID: 22960135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
    Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Zakavi SR; Caldarella C; Muoio B; Bertagna F; Ceriani L; Giovanella L
    Foot (Edinb); 2013 Dec; 23(4):140-8. PubMed ID: 23906976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
    Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
    Bachner M; Loriot Y; Gross-Goupil M; Zucali PA; Horwich A; Germa-Lluch JR; Kollmannsberger C; Stoiber F; Fléchon A; Oechsle K; Gillessen S; Oldenburg J; Cohn-Cedermark G; Daugaard G; Morelli F; Sella A; Harland S; Kerst M; Gampe J; Dittrich C; Fizazi K; De Santis M
    Ann Oncol; 2012 Jan; 23(1):59-64. PubMed ID: 21460378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
    Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V
    Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
    Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
    Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we rely on PET in the follow-up of advanced seminoma patients?
    Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
    Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.